Next Article in Journal
Genome-Wide Association Study Reveals Novel Genomic Regions for Grain Yield and Yield-Related Traits in Drought-Stressed Synthetic Hexaploid Wheat
Next Article in Special Issue
Acid Sphingomyelinase Inhibition Stabilizes Hepatic Ceramide Content and Improves Hepatic Biotransformation Capacity in a Murine Model of Polymicrobial Sepsis
Previous Article in Journal
Effects of 1-Methyltryptophan on Immune Responses and the Kynurenine Pathway after Lipopolysaccharide Challenge in Pigs
Previous Article in Special Issue
Ceramide Metabolism Balance, a Multifaceted Factor in Critical Steps of Breast Cancer Development
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 19
Issue 10
10.3390/ijms19103010
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Exogenous C8-Ceramide Induces Apoptosis by Overproduction of ROS and the Switch of Superoxide Dismutases SOD1 to SOD2 in Human Lung Cancer Cells

by
Yuli C. Chang
1,†,
Yao Fong
2,†,
Eing-Mei Tsai
3,4,
Ya-Gin Chang
5,
Han Lin Chou
5,
Chang-Yi Wu
5,6,
Yen-Ni Teng
7,
Ta-Chih Liu
1,8,
Shyng-Shiou Yuan
9 and
Chien-Chih Chiu
3,5,6,9,10,*
1
Department of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan
2
Chest Surgery, Chi-Mei Medical Center, Yung Kang City, Tainan 901, Taiwan
3
Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
4
Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
5
Department of Biotechnology, Kaohsiung Medical University, Kaohsiung 807, Taiwan
6
Department of Biological Sciences, National Sun Yat-Sen University, Kaohsiung 804, Taiwan;
7
Department of Biological Sciences and Technology, National University of Tainan, Tainan 700, Taiwan
8
Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
9
Translational Research Center, Cancer Center, Department of Medical Research, Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan
10
Research Center for Environment Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
*
Author to whom correspondence should be addressed.
†
The authors contributed equally.
Int. J. Mol. Sci. 2018, 19(10), 3010; https://doi.org/10.3390/ijms19103010
Submission received: 18 July 2018 / Revised: 25 September 2018 / Accepted: 27 September 2018 / Published: 2 October 2018
(This article belongs to the Special Issue Ceramide)
Browse Figures
Versions Notes

Abstract

:
Ceramides, abundant sphingolipids on the cell membrane, can act as signaling molecules to regulate cellular functions including cell viability. Exogenous ceramide has been shown to exert potent anti-proliferative effects against cancer cells, but little is known about how it affects reactive oxygen species (ROS) in lung cancer cells. In this study, we investigated the effect of N-octanoyl-D-erythro-sphingosine (C8-ceramide) on human non-small-cell lung cancer H1299 cells. Flow cytometry-based assays indicated that C8-ceramide increased the level of endogenous ROS in H1299 cells. Interestingly, the ratio of superoxide dismutases (SODs) SOD1 and SOD2 seem to be regulated by C8-ceramide treatment. Furthermore, the accumulation of cell cycle G1 phase and apoptotic populations in C8-ceramide-treated H1299 cells was observed. The results of the Western blot showed that C8-ceramide causes a dramatically increased protein level of cyclin D1, a critical regulator of cell cycle G1/S transition. These results suggest that C8-ceramide acts as a potent chemotherapeutic agent and may increase the endogenous ROS level by regulating the switch of SOD1 and SOD2, causing the anti-proliferation, and consequently triggering the apoptosis of NSCLC H1299 cells. Accordingly, our works may give a promising strategy for lung cancer treatment in the future.

1. Introduction

Lung cancer is a leading cause of cancer death worldwide, including in the Taiwan region. Small cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are the primary types of lung cancer. About 90% of lung cancer cases are diagnosed at an advanced stage where treatment is not available [1,2,3,4]. Approximately 80% of lung cancer belongs to NSCLC histologically [5]. The progression of the epithelial cells with undetermined clinical significance affects cell proliferation, apoptosis, angiogenesis, and activation of oncogenes [6,7]. Because NSCLC easily metastasizes into nearby tissues or other parts of the body, NSCLC patients have a relatively high mortality rate, and therefore, an effective treatment for NSCLC patients is urgent [8].
Ceramides, composed of fatty acid and sphingosine, are abundant sphingolipids on the cell membrane. Ceramides have been reported to act as signaling molecules to regulate cellular functions [9], including cellular proliferation and viability [10]. Additionally, it was well-documented that ceramides act as essential mediators in apoptosis pathways [11,12]. Exogenous ceramides have been reported as anti-cancer potential chemotherapeutics in malignancies, including pancreatic [13], breast [14], gastric [15], and hematologic [16] cancer cells. Furthermore, a previous study showed that exogenous ceramides sensitized gemcitabine-induced premature senescence [17]. Studies regarding exogenous short carbon-chain ceramides such as C2- or C6-ceramides were well-documented [12,14,18,19]. In contrast, the bioactivities of long carbon-chain ceramide were less addressed except some skin disease being used [20], because of its limited membrane permeability [21].
Superoxide dismutases (SODs), endogenous reactive oxygen species (ROS) scavenging enzymes, involves the regulation of ROS level in cells. There are three types of SODs, SOD1 (CuZn-SOD) is found in intracellular cytoplasmic spaces, SOD2 (Mn-SOD) is primarily found in the mitochondrial spaces and SOD3 (EC-SOD) is found in extracellular spaces [22]. SOD1 overexpression is frequently observed in many cancers [23], whereas SOD2 is downregulated [24]. SOD1 inhibition is considered to induce cell death potentially [25], and targeting SOD1 in lung cancer has been reported [11]. Furthermore, the expression ratio of SOD1/SOD2 seems to be a switch and plays an essential physiological role in breast cancer cells [26]. Therefore, the modulation in the ratio of SOD1/SOD2 may be a promising strategy for treating cancer cells.
Cyclin D1, an abundant protein in the G1 phase of the cell cycle, can induce global transcriptional downregulation in lymphoid neoplasms [27], and also can be critical for proliferating cells in G1/S transition [28,29]. Deregulation of cyclin D1 has been reported to be observed in cancers including breast cancer and lung cancer cells [30,31]. Cyclin D1 has been thought to promote the cellular proliferation and survival. Cyclin D1 composes a feedback loop of positively contributing to tumor growth in gastric cancer reported by Hayakawa et al. [32], and cyclin D1 links the signal of extracellular environment to upregulate proliferation of cancers including prostate cancer [33], breast cancer [34], and bladder cancer [35]. The proliferation [36] and invasion [37] of lung cancer cells can be promoted by regulating the expression of cyclin D1. However, the overexpression of cyclin D1 was also reported to be correlated with apoptosis under specific concomitant signals of arrest such as serum starvation or proliferation arrest [38]. For example, the increase of cyclin D1 artificially is sufficient to induce the apoptosis both in neural and non-neural cell types [39]. Additionally, it was also reported that dysfunction of cyclin D1 induces apoptosis of rat pheochromocytoma PC12 cells [40], and the expression level changes of cyclin D1 are related to apoptosis via G1 arrest of the cell cycle in gastric cancer cells [32].
In the study, we examined the growth inhibitory effects of C8-ceramide in NSCLC H1299 cells. Besides, the underlying mechanism of apoptosis, especially the role of cyclin D1 and the regulation of SOD1 and SOD2 was also discussed.

2. Results

2.1. C8-ceramide Exerts the Anti-Proliferation Potential against H1299 Lung Cancer Cells.

H1299 lung cancer cells were treated with increasing concentrations of C8-ceramide for 24 h, and proliferation rates were determined using Trypan blue assay. The rate of cellular proliferation of C8-ceramide-treated H1299 lung cancer cells decreased in a dose-dependent manner. The 50% inhibitory concentration (IC50, 24 h) of C8-ceramide for H1299 cells was 22.9 µM (Figure 1B).

2.2. C8-Ceramide May Cause the G1 Arrest of H1299 Cells

The cell cycle profiles of C8-ceramide treated H1299 lung cancer cells was examined using flow cytometry. Cells accumulated in the G1 phase when treated with 20 and 30 µM C8-ceramide. An increased sub-G1 population was observed at 30 and 50 µM C8-ceramide treated cells (Figure 2).
In Figure 3A, the profiles of Annexin V/PI -positive percentages were shown for the treatments with vehicle control (0.5% DMSO) or indicated concentrations (from 10 to 50 µM) of C8-ceramide for 48 h respectively. After 48 h of the C8-ceramide treatment, the Annexin V-positive percentages of H1299 cells rose in a dose-dependent manner, and the level of cleaved caspase-3 was shown (Figure 3B,C).

2.3. The Detection of Endogenous ROS in C8-Ceramide-Treated H1299 Cells

To explore whether C8-ceramide affects the endogenous ROS level of H1299 cells, we analyzed ROS generation of C8-ceramide-treated H1299 cells using flow cytometer-based 2′,7′-dichlorofluorescein diacetate (DCFDA) staining. The changes in endogenous ROS level by C8-ceramide treatment for 24 h were shown (Figure 4A). The levels of endogenous ROS were significantly increased in H1299 cells in a dose-dependent manner (* p < 0.05 and ** p < 0.001) following C8-ceramide treatment (** p < 0.001) (Figure 4B).

2.4. Assessment of Migration in C8-ceramide-treated H1299 cells

To examine whether C8-ceramide affects the cellular migration, a critical index of cancer metastasis, the wound healing assay was conducted. Image panel shows the results of wound healing assay and Boyden’s transwell assay (Figure 5). As shown in Figure 5A,B, the results showed the moderately inhibitory effect of C8-ceramide on the migration of H1299 cells, whereas the no significant changes were observed when we further assessed the anti-migration effect of C8-ceramide, showing that sub-IC50 dose (below 20 μM) of C8-ceramide is ineffective to suppress the invasion of H1299 lung cancer cells (Figure 5C,D). Therefore, the results suggesting that C8-ceramide induces anti-proliferation and apoptosis rather than anti-migration and anti-invasion in NSCLC cancer cells.

2.5. The Modulation of SOD1 and SOD2 in C8-Ceramide Treated H1299 Cells

The C8-ceramide-induced treatment modulated the levels of SOD1 and cyclin D1 in H1299 lung cancer cells on a protein level, which was examined by Western blotting in the present study. Both SOD1 (decreased) and cyclin D1 (increased) levels in C8-ceramide-treated H1299 cells were significantly changed at the concentration of 20 and 30 µM (Figure 6). In contrast, the protein levels of SOD2 were upregulated dramatically (Figure 6).

3. Discussion

The modulations of ceramides as the strategy for lung cancer therapies have been reported [12,14,41]. Both exogenous and endogenous ceramides have been reported to play essential roles in the apoptotic death of cancer cells induced by ionizing radiation [42] or chemotherapeutic agents [43,44]. However, little is known regarding the effects of long carbon-chain ceramides [45]. Among the subtype of NSCLC cells, large cell carcinoma has been reported to exhibit higher invasiveness, and it is difficult for treatment [46,47]. Therefore, we first used H1299 cells, a cell line of large cell carcinoma to examine the anti-lung cancer activity of C8-ceramide in the study. We also observed the correlations of ROS and SOD expression in lung cancer H1299 cells following exogenous C8-ceramide treatment.
The modulation of endogenous ROS are essential for cellular survival and proliferation [48] and increased ROS level could provide cancer cells with advantages of survival and growth [49]. However, excessive oxidative stresses may cause cell death. A previous study showed that superoxide dismutase SOD1 acts as an endogenous ROS scavenger and a potential contributor to the survival of the cancer cell under conditions of high oxidative stress [50]. In the study, our results showed that the C8-ceramide treatment causes the decreased expression of SOD1 concomitantly increased the level of ROS stress.
Cyclin D1 has been thought to be oncogenic [51], and cyclin D1 overexpression was frequently observed in cancers. In addition, the upregulated expression of cyclin D1 promotes the proliferation of HT29 human colon cancer cells [52]. Crebanine, an aporphine alkaloid, was reported to exert an anti-cancer activity through down-regulating cyclin D1 expression in lung adenocarcinoma A549 [53]. On the contrary, cyclin D1 overexpression was also reported to be correlated with apoptosis under specific concomitant signals of arrest such as serum starvation or proliferation arrest [38], which may due to the feedback loop between cyclin D1 and tumor suppressors. Recently, Sun’s work suggested that cyclin D1 is required for miRNA let-7-induced cancer repression and the cell death [54].
Papa and Manfredi showed that cancer cells have elevated levels of reactive oxygen species (ROS), which are generated by modulating superoxide dismutase (SOD) as an essential antioxidant enzyme [25]. Furthermore, the activity of SOD2 was decreased to 87% of breast cancer cases, whereas the levels of SOD1 and ROS were upregulated. The ratio of SOD2 to SOD1 seems to be critical for maintaining endogenous ROS in cells. Therefore, the switch mechanism of SOD1 to SOD2 may play a significant role in cellular physiology, such as invasion or proliferation of breast cancer cells. Consistently, the decrease of SOD1 and SOD2 ratio was also observed in H1299 cells following C8-ceramide treatment, suggesting that the anti-lung cancer effects of C8-ceramide may be closely correlated with the mechanism of SOD1 to SOD2 switch.
Recent studies regarding cell apoptosis showed the biological correlation between cyclin D1 and SOD1 in various human diseases, including genetic diseases and cancers [28,31,55]. The cell proliferation and cell cycle are regulated by directly interacting with cyclin D1. Cyclin D1 was up-regulated when it was involved in neurodegenerative processes related to SOD1 [30]. Furthermore, recent evidence strongly suggested the relationship between SOD and cyclin D, for example, a cell cycle signaling that is cyclin D at the neuronal G1-S checkpoint may be critical for the neuronal cell death caused by mutant SOD1 [28].
However, according to the results of those above studies, likewise, our findings suggest that C8-ceramide causes a high level of ROS that was contributed by down-regulated SOD1 and up-regulated cyclin D to promote cell cycle G1 arrest, the growth inhibition, and apoptosis of H1299 cells. Our results indicate that a cell cycle signaling changed by the up-regulation of ROS may reconstitute a critical step in the cell death pathway caused by SOD1 and cyclin D1, which was treated by exogenous long carbon-chain C8-ceramide.
Importantly, the results of our study showed that C8-ceramide induces apoptosis of H1299 cells, indicating the potential of C8-ceramide against human lung cancer cells. Menon et al.’s work investigated the regulatory role of SOD2 (MnSOD) and cyclin D1 in N-acetyl-L-cysteine (NAC)-induced G1 phase arrest in mouse fibroblast [56], and their results suggested that NAC upregulates endogenous O2 pathway and induces G1-arrest through both increasing SOD2 activity and decreasing cyclin D1 [56]. However, our results showed both SOD2 and cyclin D1 are significantly accumulated in C8-ceramide-induced G1-arrest, suggesting the cell types and drug treatments cause the different mechanism from Menon’s work.
In the study, C8-ceramide treatment may cause the switch of SOD1/SOD2 expression and the up-regulation of cyclin D1, which could sensitize NSCLC cells towards proliferation inhibition and apoptosis, and we herein presented a proposed model of the pathway accordingly (Figure 7). This model illustrated that the down-regulation of SOD1 was controlled by ROS, which resulted in negative feedback to SOD1, causing the excessive level of cyclin D1 in the H1299 cells. The up-regulation of ROS level and SOD2 were increased, and while the expression of SOD1 was decreased by the switching mechanism of SOD1/SOD2, which resulted in the up-regulation of cyclin D1 and the arrest of cell cycle G1 phase. Eventually, the cellular apoptosis is initiated, and the effector caspase-3 is activated, causing apoptosis of H1299 cells. The results of our study suggested that the anti-growth potential of exogenous long carbon-chain C8-ceramide against human non-small-cell lung cancer cells may occur through the modulation of the ratio of SOD1 and SOD2. Accordingly, the study suggested that C8-ceramide could be used for chemoprevention or chemotherapeutics of lung cancer treatment in future applications.

4. Materials and Methods

4.1. Preparation of C8-Ceramide

C8-Ceramide (d-erythro-Sphingosine, N-Octanoyl) was purchased from Calbiochem-Behring Corp. (#219540, La Jolla, CA, USA). C8-ceramide was dissolved in DMSO (as stock solutions at 5 mM), and the aliquots were stored at −20°C before assays.

4.2. Cell Cultures

Human non-small-cell lung cancer H1299 cells (large cell carcinoma) were maintained in a DMEM medium (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA, USA), 100 μg/mL streptomycin, 100 U/mL penicillin, 0.03% glutamine and 1 mM of sodium pyruvate. The cells were cultured kept at 37 °C in a humidified atmosphere with 5% CO2.

4.3. Cell Proliferation Assay

The proliferation rate was determined by a Trypan blue dye exclusion assay as previously described [57,58]. In brief, 1 × 105 H1299 cells were seeded onto a 12-well culture plate. The cells were treated with C8-ceramide at indicated concentrations for 24 h respectively. Afterward, 0.2% Trypan blue was added to the wells. Finally, the viable cells were counted by Countess® Automated Cell Counter (Invitrogen, San Diego, CA, USA). The assay was performed in triplicates, and the IC50 was calculated from the slope and intercept accordingly to the concentrations of C8-ceramide between the half-maximal proliferative inhibitions.

4.4. Apoptosis Assessment

Apoptosis was detected by Annexin/PI double staining as previously described with minor modifications [59]. Cells were treated with indicated concentrations of C8-ceramide for 24 h respectively. Cells were harvested and stained with 10 μg/mL of Annexin V-fluorescein isothiocyanate and 5 μg/mL of PI. Then cells were measured with a flow cytometer (FACSCalibur, Becton-Dickinson, Mansfield, MA, USA). Healthy cells (Annexin V−/PI−), the necrotic (Annexin V−/PI+), early apoptotic (Annexin V+/PI−) and late apoptotic cells (Annexin V+/PI+).

4.5. Cell Cycle Distribution

Propidium iodide (PI) (Sigma-Aldrich St. Louis, MO, USA) was used for assessing DNA content. In brief, cells were treated with indicated concentrations of C8-ceramide for 24 h respectively. After harvest, cells were fixed with 70% ethanol and washed with phosphate-buffered saline (PBS). After centrifugation, cells were incubated with 10 μg/mL RNase A and 10 μg/mL propidium iodide in PBS for 15 min at room temperature in the dark. The distributions of the cell cycle were analyzed using a BD LSRII flow cytometer (Becton Dickinson, San Jose, CA, USA).

4.6. Flow Cytometry-based ROS assessment

The changes in endogenous ROS levels were assessed using the redox-sensitive fluorescence indicator 2′,7′-dichlorofluorescein diacetate (DCFDA) (Sigma-Aldrich, St. Louis, MO, USA). The ROS assessment was described previously [56]. Briefly, cells were treated with or without C8-ceramide for 24 h respectively and then harvested and stained with the oxidative dye 100 nM DCFDA in PBS for 30 min at 37 °C. The measurement wavelengths for excitation and emission were 485 and 530 nm, respectively.

4.7. Wound Healing Assay

The cells were seeded and grown on a 12-well plate for overnight. Then cells were scratched by a 200 μL tip to generate a wound area. Cells were further incubated with medium containing 8% FBS media at 37 °C for 12 h for reconstructing the wound area. The wound areas were measured by a software TScratch (http://www.cse-lab.ethz.ch) [59].

4.8. Boyden’s Transwell Assay

The invasion ability was performed by a 12-well plate combined with inserts with polycarbonate filters (8-μm pore size). Briefly, the lower well contained 800 µL of medium containing 10% FBS. One hundred thousand H1299 cells in serum-free medium were seeded onto a transwell insert (Greiner) and were incubated for 16 h. Invaded cells were fixed with 4% paraformaldehyde and then stained with Giemsa (Merck). All stained cells were counted under a microscope (TE2000-U; Nikon, Tokyo, Japan)

4.9. Western Blotting Assay

In brief, cells were collected for lysate preparation. Forty μg of protein lysates were loaded and electrophoresed on 10% SDS-polyacrylamide gel and then transferred to nitrocellulose membranes, and then were blocked with 5% nonfat milk. Subsequently, the membranes were reacted with primary antibodies against SOD1 (GeneTex Co., Cat No. GTX100659, Irvine, CA, USA), SOD2 (GeneTex Co., Cat No. GTX116093, Irvine, CA, USA), cyclin D1 (GeneTex Co., Cat No. GTX112874, Irvine, CA, USA), caspase-3 (Imgenex, Cat No. IMG-144A, Imgenex, San Diego, CA, USA), β-actin (Santa Cruz Biotech, Cat No. #sc-8432, Santa Cruz, CA, USA). The membranes were further reacted with the corresponding secondary antibodies. The chemiluminescence detection kit (ECLTM, Amersham Piscataway, NJ, USA) was used for detecting specific proteins.

4.10. Statistical Analysis

All data of the study were presented as mean ± S.D. Differences between vehicle controls and experimental groups were analyzed by one-way ANOVA test.

Author Contributions

Conceptualization, C.-C.C., Y.F. and Y.C.C.; Methodology, Y.-G.C, H.-L.C and Y.-N.T.; Software, H.-L.C.; Validation, Y.-G.C and H.-L.C.; Formal Analysis, Y.C.C and Y.-G.C.; Investigation, C.-C.C., Y.F. and Y.C.C; Resources, E.-M.T, C.-Y.W., S.-S.Y. and T.-C.L; Data Curation, Y.-G.C.; Writing-Original Draft Preparation, C.-C.C. Y.F. and Y.C.C.; Writing-Review & Editing, C.-C.C..; Supervision, C.-C.C.; Funding Acquisition, C.-C.C.

Funding

The study was supported by following grants, the grant MOST106-2320-B-037-012 and 107-2320-B-037-023 from the Ministry of Science and Technology, Taiwan; by the grants 104CMKMU006 from ChiMei-KMU Joint Research Project; by the grant #NSYSU-KMU106-P019 and #NSYSU-KMU107-P002 from the NSYSU-KMU; by the grant Aim for the Top Universities Grant, No. KMU-TP105A07 from Kaohsiung Medical University, Taiwan.

Acknowledgments

We would like to thank the Center for Research Resources and Development (Kaohsiung Medical University) for supporting the flow cytometer and confocal laser scanning microscope system.

Conflicts of Interest

The authors declare there are no conflicts of interest.

References

  1. Okazaki, I.; Ishikawa, S.; Sohara, Y. Genes Associated with Susceptibility to Lung Adenocarcinoma among Never Smokers Suggest the Mechanism of Disease. Anticancer Res. 2014, 34, 5229–5240. [Google Scholar] [PubMed]
  2. Tseng, R.C.; Lee, C.C.; Hsu, H.S.; Tzao, C.; Wang, Y.C. Distinct Hic1-Sirt1-P53 Loop Deregulation in Lung Squamous Carcinoma and Adenocarcinoma Patients. Neoplasia 2009, 11, 763–770. [Google Scholar] [CrossRef] [PubMed]
  3. Pirker, R.; Minar, W. Chemotherapy of Advanced Non-Small Cell Lung Cancer. Front. Radiat. Ther. Oncol. 2010, 42, 157–163. [Google Scholar] [PubMed]
  4. Alghamdi, H.I.; Alshehri, A.F.; Farhat, G.N. An Overview of Mortality & Predictors of Small-Cell and Non-Small Cell Lung Cancer among Saudi Patients. J. Epidemiol. Glob. Health 2018, 7, S1–S6. [Google Scholar] [PubMed]
  5. Travis, W.D.; Brambilla, E.; Noguchi, M.; Nicholson, G.A.; Geisinger, K.; Yatabe, Y.; Powell, C.A.; Beer, D.; Riely, G.; Garg, K.; et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: International Multidisciplinary Classification of Lung Adenocarcinoma: Executive Summary. Proc. Am. Thorac. Soc. 2011, 8, 381–385. [Google Scholar] [PubMed]
  6. Dacic, S.; Nikiforova, M.N. Present and Future Molecular Testing of Lung Carcinoma. Adv. Anat. Pathol. 2014, 21, 94–99. [Google Scholar] [CrossRef] [PubMed]
  7. Wagner, T.D.; Yang, G.Y. The Role of Chemotherapy and Radiation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC). Curr. Drug Targets. 2010, 11, 67–73. [Google Scholar] [CrossRef] [PubMed]
  8. Cheng, A.M.; Wood, D.E. Minimally Invasive Resection of Early Lung Cancers. Oncology 2015, 29. [Google Scholar]
  9. Skolova, B.; Hudska, K.; Pullmannova, P.; Kovacik, A.; Palat, K.; Roh, J.; Fleddermann, J.; Estrela-Lopis, I.; Vavrova, K. Different Phase Behavior and Packing of Ceramides with Long (C16) and Very Long (C24) Acyls in Model Membranes: Infrared Spectroscopy Using Deuterated Lipids. J. Phys. Chem. B 2014, 118, 10460–10470. [Google Scholar] [CrossRef] [PubMed]
  10. Korbelik, M.; Banath, J.; Sun, J.; Canals, D.; Hannun, Y.A.; Separovic, D. Ceramide and Sphingosine-1-Phosphate Act as Photodynamic Therapy-Elicited Damage-Associated Molecular Patterns: Cell Surface Exposure. Int. Immunopharmacol. 2014, 20, 359–365. [Google Scholar] [CrossRef] [PubMed]
  11. Glasauer, A.; Sena, L.A.; Diebold, L.P.; Mazar, A.P.; Chandel, N.S. Targeting Sod1 Reduces Experimental Non-Small-Cell Lung Cancer. J. Clin. Investig. 2014, 124, 117–128. [Google Scholar] [CrossRef] [PubMed]
  12. Goldkorn, T.; Chung, S.; Filosto, S. Lung Cancer and Lung Injury: The Dual Role of Ceramide. Handb. Exp. Pharmacol. 2013, 93–113. [Google Scholar]
  13. Morad, S.A.; Messner, M.C.; Levin, J.C.; Abdelmageed, N.; Park, H.; Merrill Jr, A.H.; Cabot, M.C. Potential Role of Acid Ceramidase in Conversion of Cytostatic to Cytotoxic End-Point in Pancreatic Cancer Cells. Cancer Chemother. Pharmacol. 2013, 71, 635–645. [Google Scholar] [CrossRef] [PubMed]
  14. Flowers, M.; Fabrias, G.; Delgado, A.; Casas, J.; Abad, J.L.; Cabot, M.C. C6-Ceramide and Targeted Inhibition of Acid Ceramidase Induce Synergistic Decreases in Breast Cancer Cell Growth. Breast Cancer Res. Treat. 2012, 133, 447–458. [Google Scholar] [CrossRef] [PubMed]
  15. Huang, H.; Zhang, Y.; Liu, X.; Li, Z.; Xu, W.; He, S.; Huang, Y.; Zhang, H. Acid Sphingomyelinase Contributes to Evodiamine-Induced Apoptosis in Human Gastric Cancer Sgc-7901 Cells. DNA Cell Biol. 2011, 30, 407–412. [Google Scholar] [CrossRef] [PubMed]
  16. Fabrias, G.; Bedia, C.; Casas, J.; Abad, J.L.; Delgado, A. Ceramidases in Hematological Malignancies: Senseless or Neglected Target? Anticancer Agents Med. Chem. 2011, 11, 830–843. [Google Scholar] [CrossRef] [PubMed]
  17. Modrak, D.E.; Leon, E.; Goldenberg, D.M.; Gold, D.V. Ceramide Regulates Gemcitabine-Induced Senescence and Apoptosis in Human Pancreatic Cancer Cell Lines. Mol. Cancer Res. 2009, 7, 890–896. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Demarchi, F.; Bertoli, C.; Greer, P.A.; Schneider, C. Ceramide Triggers an Nf-Κb-Dependent Survival Pathway through Calpain. Cell Death Differ. 2005, 12, 512–522. [Google Scholar] [CrossRef] [PubMed]
  19. Xu, L.; Deng, X. Suppression of Cancer Cell Migration and Invasion by Protein Phosphatase 2a through Dephosphorylation of mu- and m-Calpains. J. Biol. Chem. 2006, 281, 35567–35575. [Google Scholar] [CrossRef] [PubMed]
  20. Ohno, Y. Elucidation of the Synthetic Mechanism of Acylceramide, an Essential Lipid for Skin Barrier Function. Yakugaku Zasshi 2017, 137, 1201–1208. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Hamanaka, S.; Suzuki, A.; Hara, M.; Nishio, H.; Otsuka, F.; Uchida, Y. Human Epidermal Glucosylceramides Are Major Precursors of Stratum Corneum Ceramides. J. Investig. Dermatol. 2002, 119, 416–423. [Google Scholar] [CrossRef] [PubMed]
  22. Zelko, I.N.; Mariani, T.J.; Folz, R.J. Superoxide Dismutase Multigene Family: A Comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and Ec-SOD (SOD3) Gene Structures, Evolution, and Expression. Free Radic. Biol. Med. 2002, 33, 337–349. [Google Scholar] [CrossRef]
  23. Kuzu, M.; Kandemir, F.M.; Yildirim, S.; Kucukler, S.; Caglayan, C.; Turk, E. Morin Attenuates Doxorubicin-Induced Heart and Brain Damage by Reducing Oxidative Stress, Inflammation and Apoptosis. Biomed. Pharmacother. 2018, 106, 443–453. [Google Scholar] [CrossRef] [PubMed]
  24. Girerd, S.; Tosca, L.; Herault, O.; Vignon, C.; Biard, D.; Aggoune, D.; Dkhissi, F.; Bonnet, M.L.; Sorel, N.; Desterke, C.; et al. Superoxide Dismutase 2 (SOD2) Contributes to Genetic Stability of Native and T315i-Mutated Bcr-Abl Expressing Leukemic Cells. Biochem. Biophys. Res. Commun. 2018, 498, 715–722. [Google Scholar] [CrossRef] [PubMed]
  25. Papa, L.; Manfredi, G.; Germain, D. Sod1, an Unexpected Novel Target for Cancer Therapy. Genes Cancer 2014, 5, 15–21. [Google Scholar] [PubMed]
  26. Papa, L.; Hahn, M.; Marsh, E.L.; Evans, B.S.; Germain, D. Sod2 to Sod1 Switch in Breast Cancer. J. Biol. Chem. 2014, 289, 5412–5416. [Google Scholar] [CrossRef] [PubMed]
  27. Albero, R.; Enjuanes, A.; Demajo, S.; Castellano, G.; Pinyol, M.; García, N.; Capdevila, C.; Clot, G.; Suárez-Cisneros, H.; Shimada, M.; et al. Cyclin D1 Overexpression Induces Global Transcriptional Downregulation in Lymphoid Neosplasms. J. Clin. Investig. 2018. [Google Scholar] [CrossRef] [PubMed]
  28. Nguyen, M.D.; Boudreau, M.; Kriz, J.; Couillard-Després, S.; Kaplan, D.R.; Julien, J.P. Cell Cycle Regulators in the Neuronal Death Pathway of Amyotrophic Lateral Sclerosis Caused by Mutant Superoxide Dismutase 1. J. Neurosci. 2003, 23, 2131–2140. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Yang, Z.H.; Zhou, C.L.; Zhu, H.; Li, J.H.; He, C.D. A Functional SNP in the Mdm2 Promoter Mediates E2f1 Affinity to Modulate Cyclin D1 Expression in Tumor Cell Proliferation. Asian Pac. J. Cancer Prev. 2014, 15, 3817–3823. [Google Scholar] [CrossRef] [PubMed]
  30. Bethea, C.L.; Reddy, A.P. Effect of Ovarian Hormones on Survival Genes in Laser Captured Serotonin Neurons from Macaques. J. Neurochem. 2008, 105, 1129–1143. [Google Scholar] [CrossRef] [PubMed]
  31. Wu, F.H.; Luo, L.Q.; Liu, Y.; Zhan, Q.X.; Luo, C.; Luo, J.; Zhang, G.M.; Feng, Z.H. Cyclin D1b Splice Variant Promotes Alphavbeta3-Mediated Adhesion and Invasive Migration of Breast Cancer Cells. Cancer Lett. 2014, 355, 159–167. [Google Scholar] [CrossRef] [PubMed]
  32. Hayakawa, Y.; Hirata, Y.; Nakagawa, H.; Sakamoto, K.; Hikiba, Y.; Kinoshita, H.; Nakata, W.; Takahashi, R.; Tateishi, K.; Tada, M. Apoptosis Signal-Regulating Kinase 1 and Cyclin D1 Compose a Positive Feedback Loop Contributing to Tumor Growth in Gastric Cancer. Proc. Natl. Acad. Sci. USA 2011, 108, 780–785. [Google Scholar] [CrossRef] [PubMed]
  33. Aaltomaa, S.; Kärjä, V.; Lipponen, P. Isotalo, T. Kankkunen, J.P. Talja, M.; Mokka, R. Expression of Ki-67, Cyclin D1 and Apoptosis Markers Correlated with Survival in Prostate Cancer Patients Treated by Radical Prostatectomy. Anticancer Res. 2006, 26, 4873–4878. [Google Scholar] [PubMed]
  34. Martin, J.M.C.; Balkenende, A.; Verschoor, T.; Lallemand, F.; Michalides, R. Cyclin D1 Overexpression Enhances Radiation-Induced Apoptosis and Radiosensitivity in a Breast Tumor Cell Line. Cancer Res. 1999, 59, 1134–1140. [Google Scholar]
  35. Moonen, L.; Ong, F.; Gallee, M.; Verheij, M.; Horenblas, S.; Hart, A.A.; Bartelink, H. Apoptosis, Proliferation and P53, Cyclin D1, and Retinoblastoma Gene Expression in Relation to Radiation Response in Transitional Cell Carcinoma of the Bladder. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49, 1305–1310. [Google Scholar] [CrossRef]
  36. Xie, X.; Xiao, H.; Ding, F.; Zhong, H.; Zhu, J.; Ma, N.; Mei, J. Over-Expression of Prolyl Hydroxylase-1 Blocks NF-KappaB-Mediated Cyclin D1 Expression and Proliferation in Lung Carcinoma Cells. Cancer Genet. 2014, 207, 188–194. [Google Scholar] [CrossRef] [PubMed]
  37. Xie, C.; Jiang, G.; Fan, C.; Zhang, X.; Zhang, Y.; Miao, Y.; Lin, X.; Wu, J.; Wang, L.; Liu, Y.; et al. ARMC8α Promotes Proliferation and Invasion of Non-Small Cell Lung Cancer Cells by Activating the Canonical Wnt Signaling Pathway. Tumour. Biol. 2014, 35, 8903–8911. [Google Scholar] [CrossRef] [PubMed]
  38. Weng, X.; Zhu, S.Q.; Cui, H.J. Artesunate Inhibits Proliferation of Glioblastoma Cells by Arresting Cell Cycle. Zhongguo Zhong Yao Za Zhi 2018, 43, 772–778. [Google Scholar] [PubMed]
  39. Kranenburg, O.; van der Eb, A.J.; Zantema, A. Cyclin D1 Is an Essential Mediator of Apoptotic Neuronal Cell Death. EMBO J. 1996, 15, 46–54. [Google Scholar] [CrossRef] [PubMed]
  40. Katayama, K.; Dobashi, Y.; Kitagawa, M.; Kamekura, S.; Kawai, M.; Kadoya, Y.; Kameya, T. Overexpression of Cdk4/Cyclin D1 Induces Apoptosis in Pc12 Cells in the Presence of Trophic Support. FEBS Lett. 2001, 509, 382–388. [Google Scholar] [CrossRef]
  41. Gao, M.Q.; Gao, H.; Han, M.; Liu, K.L.; Peng, J.J.; Han, Y.T. Hispidulin Suppresses Tumor Growth and Metastasis in Renal Cell Carcinoma by Modulating Ceramide-Sphingosine 1-Phosphate Rheostat. Am. J. Cancer Res. 2017, 7, 1501–1514. [Google Scholar] [PubMed]
  42. Hage-Sleiman, R.; Esmerian, M.O.; Kobeissy, H.; Dbaibo, G. P53 and Ceramide as Collaborators in the Stress Response. Int. J. Mol. Sci. 2013, 14, 4982–5012. [Google Scholar] [CrossRef] [PubMed]
  43. Kurinna, S.M.; Tsao, C.C.; Nica, A.F.; Jiffar, T.; Ruvolo, P.P. Ceramide Promotes Apoptosis in Lung Cancer-Derived A549 Cells by a Mechanism Involving C-Jun Nh2-Terminal Kinase. Cancer Res. 2004, 64, 7852–7856. [Google Scholar] [CrossRef] [PubMed]
  44. Dinkins, M.B.; Dasgupta, S.; Wang, G.; Zhu, G.; He, Q.; Kong, J.N.; Bieberich, E. The 5xfad Mouse Model of Alzheimer’s Disease Exhibits an Age-Dependent Increase in Anti-Ceramide Igg and Exogenous Administration of Ceramide Further Increases Anti-Ceramide Titers and Amyloid Plaque Burden. J. Alzheimers Dis. 2015. [Google Scholar] [CrossRef] [PubMed]
  45. Zheng, W.; Kollmeyer, J.; Symolon, H.; Momin, A.; Munter, E.; Wang, E.; Kelly, S.; Allegood, J.C.; Liu, Y.; Peng, Q.; Ramaraju, H. Ceramides and Other Bioactive Sphingolipid Backbones in Health and Disease: Lipidomic Analysis, Metabolism and Roles in Membrane Structure, Dynamics, Signaling and Autophagy. Biochim. Biophys. Acta. 2006, 1758, 1864–1884. [Google Scholar] [CrossRef] [PubMed]
  46. Seo, M.; Nam, H.J.; Kim, S.Y.; Juhnn, Y.S. Inhibitory Heterotrimeric Gtp-Binding Proteins Inhibit Hydrogen Peroxide-Induced Apoptosis by up-Regulation of Bcl-2 Via Nf-Kappab in H1299 Human Lung Cancer Cells. Biochem. Biophys. Res. Commun. 2009, 381, 153–158. [Google Scholar] [CrossRef] [PubMed]
  47. Shatz, M.; Lustig, G.; Reich, R.; Liscovitch, M. Caveolin-1 Mutants P132l and Y14f Are Dominant Negative Regulators of Invasion, Migration and Aggregation in H1299 Lung Cancer Cells. Exp. Cell Res. 2010, 316, 1748–1762. [Google Scholar] [CrossRef] [PubMed]
  48. Sgarbi, G.; Gorini, G.; Liuzzi, F.; Solaini, G.; Baracca, A. Hypoxia and IF 1 Expression Promote Ros Decrease in Cancer Cells. Cells 2018, 7. [Google Scholar] [CrossRef] [PubMed]
  49. Yang, L.; Zheng, L.Y.; Tian, Y.; Zhang, Z.Q.; Dong, W.L.; Wang, X.F.; Zhang, X.Y.; Cao, C. C6 Ceramide Dramatically Enhances Docetaxel-Induced Growth Inhibition and Apoptosis in Cultured Breast Cancer Cells: A. Mechanism Study. Exp. Cell Res. 2015, 332, 47–59. [Google Scholar] [CrossRef] [PubMed]
  50. Martín, D.; Salinas, M.; Fujita, N.; Tsuruo, T.; Cuadrado, A. Ceramide and Reactive Oxygen Species Generated by H2o2 Induce Caspase-3-Independent Degradation of Akt/Protein Kinase, B. J. Biol. Chem. 2002, 277, 42943–42952. [Google Scholar] [CrossRef] [PubMed]
  51. Chen, X.; Long, X.; Liao, Y.; Zheng, J. Lycorine Inhibits the Proliferation and Promotes Apoptosis of Sgc-7901 Gastric Cancer Cells by Downregulating Expression of Cyclin D1. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2018, 34, 354–358. [Google Scholar] [PubMed]
  52. Guo, X.; Li, W.; Wang, Q.; Yang, H.S. Akt Activation by Pdcd4 Knockdown up-Regulates Cyclin D1 Expression and Promotes Cell Proliferation. Genes Cancer 2011, 2, 818–828. [Google Scholar] [CrossRef] [PubMed]
  53. Yodkeeree, S.; Pompimon, W.; Limtrakul, P. Crebanine, an Aporphine Alkaloid, Sensitizes TNF-alpha-Induced Apoptosis and Suppressed Invasion of Human Lung Adenocarcinoma Cells A549 by Blocking NF-KappaB-Regulated Gene Products. Tumour Biol. 2014, 35, 8615–8624. [Google Scholar] [CrossRef] [PubMed]
  54. Sun, X.; Tang, S.C.; Xu, C.; Wang, C.; Qin, S.; Du, N.; Liu, J.; Zhang, Y.; Li, X.; Luo, G.; et al. Dicer1 Regulated Let-7 Expression Levels in P53-Induced Cancer Repression Requires Cyclin D1. J. Cell Mol. Med. 2015, 19, 1357–1365. [Google Scholar] [CrossRef] [PubMed]
  55. Menon, S.G.; Sarsour, E.H.; Kalen, A.L.; Venkataraman, S.; Hitchler, M.J.; Domann, F.E.; Oberley, L.W.; Goswami, P.C. Superoxide Signaling Mediates N-Acetyl-l-Cysteine-Induced G1 Arrest: Regulatory Role of Cyclin D1 and Manganese Superoxide Dismutase. Cancer Res. 2007, 67, 6392–6399. [Google Scholar] [CrossRef] [PubMed]
  56. Fang, H.Y.; Wang, H.M.; Chang, K.F.; Hu, H.T.; Hwang, L.J.; Fu, T.F.; Lin, Y.C.; Chang, W.C.; Chiu, T.P.; Wen, Z.H.; et al. Feruloyl-L-Arabinose Attenuates Migration, Invasion and Production of Reactive Oxygen Species in H1299 Lung Cancer Cells. Food Chem. Toxicol. 2013, 58, 459–466. [Google Scholar] [CrossRef] [PubMed]
  57. Chiu, C.C.; Chang, H.W.; Chuang, D.W.; Chang, F.R.; Chang, Y.C.; Cheng, Y.S.; Tsai, M.T.; Chen, W.Y.; Lee, S.S.; Wang, C.K.; et al. Fern Plant-Derived Protoapigenone Leads to DNA Damage, Apoptosis, and G(2)/M Arrest in Lung Cancer; et al. Cell Line H1299. DNA Cell Biol. 2009, 28, 501–506. [Google Scholar] [CrossRef] [PubMed]
  58. Chiu, C.C.; Liu, P.L.; Huang, K.J.; Wang, H.M.; Chang, K.F.; Chou, C.K.; Chang, F.R.; Chong, I.W.; Fang, K.; Chen, J.S.; et al. Goniothalamin Inhibits Growth of Human Lung Cancer Cells through DNA Damage, Apoptosis, and Reduced Migration Ability. J. Agric. Food Chem. 2011, 59, 4288–4293. [Google Scholar] [CrossRef] [PubMed]
  59. Chiu, C.C.; Chou, H.L.; Chen, B.H.; Chang, K.F.; Tseng, C.H.; Fong, Y.; Fu, T.F.; Chang, H.W.; Wu, C.Y.; Tsai, E.M.; et al. BPIQ, a Novel Synthetic Quinoline Derivative, Inhibits Growth and Induces Mitochondrial Apoptosis of Lung Cancer Cells in Vitro and in Zebrafish Xenograft Model. BMC Cancer 2015, 15, 962. [Google Scholar] [CrossRef] [PubMed]
Ijms 19 03010 g001 550
Figure 1. (A) Structure of the C8-ceramide (N-octanoyl-d-erythro-sphingosine). (B) The quantitative analysis of cell proliferation assay showed the inhibition of growth in a dose-dependent manner (* p < 0.05, ** p < 0.001 for C8-ceramide treatment versus respective control).
Figure 1. (A) Structure of the C8-ceramide (N-octanoyl-d-erythro-sphingosine). (B) The quantitative analysis of cell proliferation assay showed the inhibition of growth in a dose-dependent manner (* p < 0.05, ** p < 0.001 for C8-ceramide treatment versus respective control).
Ijms 19 03010 g001
Ijms 19 03010 g002 550
Figure 2. C8-ceramide-induced cell arrest of G1 in H1299 cells. Cells were treated with indicated concentrations (from 10 to 50 µM) of C8-ceramide for 24 h respectively. (A) Representative cell cycle distribution in C8-ceramide-treated H1299 cells. (B) The results of quantitative analysis. C8-ceramide induces the apoptosis of H1299 cells in a dose-dependent manner.
Figure 2. C8-ceramide-induced cell arrest of G1 in H1299 cells. Cells were treated with indicated concentrations (from 10 to 50 µM) of C8-ceramide for 24 h respectively. (A) Representative cell cycle distribution in C8-ceramide-treated H1299 cells. (B) The results of quantitative analysis. C8-ceramide induces the apoptosis of H1299 cells in a dose-dependent manner.
Ijms 19 03010 g002
Ijms 19 03010 g003 550
Figure 3. C8-ceramide-induced apoptotic profiles of lung cancer H1299 cells. Cells were treated with indicated concentrations (from 10 to 50 µM) C8-ceramide for 24 h and 48 h respectively. (A) Representative profiles of apoptosis detected by Annexin V/PI double staining in C8-ceramide-treated H1299 cells for 48 h. (B) Population assessment of early and late-stage apoptosis. * p < 0.05, ** p < 0.001 for C8-ceramide treatment versus respective control. (C) The results of the quantitative analysis for apoptosis population (%). Data, mean ± SD (n = 3). (D) The proteolytic activation (cleaved form) of caspase-3 in C8-ceramide treated H1299 cells. β-actin as an internal control.
Figure 3. C8-ceramide-induced apoptotic profiles of lung cancer H1299 cells. Cells were treated with indicated concentrations (from 10 to 50 µM) C8-ceramide for 24 h and 48 h respectively. (A) Representative profiles of apoptosis detected by Annexin V/PI double staining in C8-ceramide-treated H1299 cells for 48 h. (B) Population assessment of early and late-stage apoptosis. * p < 0.05, ** p < 0.001 for C8-ceramide treatment versus respective control. (C) The results of the quantitative analysis for apoptosis population (%). Data, mean ± SD (n = 3). (D) The proteolytic activation (cleaved form) of caspase-3 in C8-ceramide treated H1299 cells. β-actin as an internal control.
Ijms 19 03010 g003
Ijms 19 03010 g004 550
Figure 4. C8-ceramide increases the level of ROS in H1299 cells. (A) Flow cytometry-based ROS assessment for C8-ceramide-treated cells. Cells were treated with indicated concentrations (from 0 to 30 µM) of C8-ceramide for 24 h respectively. Positive % was indicated in each panel. PC: positive control, 1 mM H2O2. CON: vehicle control. NC: negative control, unstained cells. Quantitative analysis. Data presented as mean ± S.D. in triplicate. Asterisks indicated statistically significant differences compared with those of the control (* p < 0.05 and ** p < 0.001 for control versus C8-ceramide treatment respectively). (B) The quantitative analysis. Data presented as mean ± S.D. in triplicates. Five μM of camptothecin (CPT) as a positive control. Asterisks indicated statistically significant differences compared with those of the control (** p < 0.001 for C8-ceramide treatment versus respective control in 6 and 12 h).
Figure 4. C8-ceramide increases the level of ROS in H1299 cells. (A) Flow cytometry-based ROS assessment for C8-ceramide-treated cells. Cells were treated with indicated concentrations (from 0 to 30 µM) of C8-ceramide for 24 h respectively. Positive % was indicated in each panel. PC: positive control, 1 mM H2O2. CON: vehicle control. NC: negative control, unstained cells. Quantitative analysis. Data presented as mean ± S.D. in triplicate. Asterisks indicated statistically significant differences compared with those of the control (* p < 0.05 and ** p < 0.001 for control versus C8-ceramide treatment respectively). (B) The quantitative analysis. Data presented as mean ± S.D. in triplicates. Five μM of camptothecin (CPT) as a positive control. Asterisks indicated statistically significant differences compared with those of the control (** p < 0.001 for C8-ceramide treatment versus respective control in 6 and 12 h).
Ijms 19 03010 g004
Ijms 19 03010 g005 550
Figure 5. The effects of C8-ceramide on the migration and invasion of H1299 lung cancer cells. (A) A confluent culture of H1299 cells was seeded onto a 12-well plate, and cells have created a gap with a 200 µL tip. The cells were treated with indicated concentrations (from 0 to 50 µM) of C8-ceramide for 24 h respectively. (B) Quantitative analysis of (A) (* p < 0.05 and ** p < 0.001 for C8-ceramide treatment versus respective control). (C) Boyden’s transwell assay was conducted to examine the effect of C8-ceramide on the invasion of H1299 cells. (D) Quantitative analysis of (C) Magnification: 100×.
Figure 5. The effects of C8-ceramide on the migration and invasion of H1299 lung cancer cells. (A) A confluent culture of H1299 cells was seeded onto a 12-well plate, and cells have created a gap with a 200 µL tip. The cells were treated with indicated concentrations (from 0 to 50 µM) of C8-ceramide for 24 h respectively. (B) Quantitative analysis of (A) (* p < 0.05 and ** p < 0.001 for C8-ceramide treatment versus respective control). (C) Boyden’s transwell assay was conducted to examine the effect of C8-ceramide on the invasion of H1299 cells. (D) Quantitative analysis of (C) Magnification: 100×.
Ijms 19 03010 g005
Ijms 19 03010 g006 550
Figure 6. Regulation of SOD1/2 and cyclin D1 proteins induced by C8-ceramide. After C8-ceramide treatment, SOD1 downregulation may be controlled by ROS, which can negative feedback to SOD1 switched SOD2 and then modulated the expression of cyclin D1. β-actin as an internal control.
Figure 6. Regulation of SOD1/2 and cyclin D1 proteins induced by C8-ceramide. After C8-ceramide treatment, SOD1 downregulation may be controlled by ROS, which can negative feedback to SOD1 switched SOD2 and then modulated the expression of cyclin D1. β-actin as an internal control.
Ijms 19 03010 g006
Ijms 19 03010 g007 550
Figure 7. A proposed model of C8-ceramide-induced apoptosis and anti-proliferation of non-small-cell lung cancer cells by modulating the differential expressions of superoxide dismutases and cell cycle G1 arrest. After C8-ceramide treatment, the SOD1 to SOD2 switch stimulated by ROS induces the excess accumulation of cyclin D1, a feedback loop, which in turn causes cell cycle G1 arrest. Eventually, C8-ceramide induces the growth arrest and the apoptotic cell death in lung cancer H1299 cells. The upwards arrows and downwards arrows indicate the upregulation and downregulation respectively.
Figure 7. A proposed model of C8-ceramide-induced apoptosis and anti-proliferation of non-small-cell lung cancer cells by modulating the differential expressions of superoxide dismutases and cell cycle G1 arrest. After C8-ceramide treatment, the SOD1 to SOD2 switch stimulated by ROS induces the excess accumulation of cyclin D1, a feedback loop, which in turn causes cell cycle G1 arrest. Eventually, C8-ceramide induces the growth arrest and the apoptotic cell death in lung cancer H1299 cells. The upwards arrows and downwards arrows indicate the upregulation and downregulation respectively.
Ijms 19 03010 g007

Share and Cite

MDPI and ACS Style

Chang, Y.C.; Fong, Y.; Tsai, E.-M.; Chang, Y.-G.; Chou, H.L.; Wu, C.-Y.; Teng, Y.-N.; Liu, T.-C.; Yuan, S.-S.; Chiu, C.-C. Exogenous C8-Ceramide Induces Apoptosis by Overproduction of ROS and the Switch of Superoxide Dismutases SOD1 to SOD2 in Human Lung Cancer Cells. Int. J. Mol. Sci. 2018, 19, 3010. https://doi.org/10.3390/ijms19103010

AMA Style

Chang YC, Fong Y, Tsai E-M, Chang Y-G, Chou HL, Wu C-Y, Teng Y-N, Liu T-C, Yuan S-S, Chiu C-C. Exogenous C8-Ceramide Induces Apoptosis by Overproduction of ROS and the Switch of Superoxide Dismutases SOD1 to SOD2 in Human Lung Cancer Cells. International Journal of Molecular Sciences. 2018; 19(10):3010. https://doi.org/10.3390/ijms19103010

Chicago/Turabian Style

Chang, Yuli C., Yao Fong, Eing-Mei Tsai, Ya-Gin Chang, Han Lin Chou, Chang-Yi Wu, Yen-Ni Teng, Ta-Chih Liu, Shyng-Shiou Yuan, and Chien-Chih Chiu. 2018. "Exogenous C8-Ceramide Induces Apoptosis by Overproduction of ROS and the Switch of Superoxide Dismutases SOD1 to SOD2 in Human Lung Cancer Cells" International Journal of Molecular Sciences 19, no. 10: 3010. https://doi.org/10.3390/ijms19103010

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop